Revitope Oncology, Inc. logo

Revitope Oncology, Inc.

Revitope Oncology, is a cancer immunotherapy company, develops a platform based on redirecting viral immunity for the purpose of developing compounds to treat solid tumors and hematologic malignancies. Revitope is located at LabCentral, Cambridge.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.revitope.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
700 Main Street, North, MA 02139 USA
Cambridge
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/revitope” connections=”true” suffix=””]

Revitopes antibody peptide epitope complex (APEC) technology, comprised of an antibody conjugated to a peptide containing a protease cleavable site and an immuno-dominant viral epitope. It selectively delivers an immunodominant viral peptide to the tumor cell, thereby activating exisiting T cells that recognize the tumor as virally infected, and kill it.

In Feb 2016, Revitope Oncology raised $8.5 Mn to continue development of its novel immunotherapy platform for the treatment of solid tumors and hematologic malignancies.